Macrocytic anemia is a hematological condition characterized by the presence of enlarged red blood cells (RBCs), typically reflected by an increased mean corpuscular volume (MCV >100 fL). In pediatric practice, as outlined in Nelson Textbook of Pediatrics, macrocytic anemia represents an important diagnostic category that often signals underlying nutritional deficiencies, bone marrow disorders, or systemic disease.

---

Classification of Macrocytic Anemia

Macrocytic anemia can broadly be divided into:

1. Megaloblastic Macrocytic Anemia
   • Caused by impaired DNA synthesis
   • Characterized by megaloblasts in the bone marrow
2. Non-Megaloblastic Macrocytic Anemia
   • Not associated with defective DNA synthesis
   • Often due to membrane abnormalities or increased reticulocyte count

---

Etiology

1. Megaloblastic Causes

• Vitamin B12 deficiency
  • Dietary deficiency (rare in children unless strict vegan diet)
  • Malabsorption (e.g., pernicious anemia, ileal disease)
• Folate deficiency
  • Poor dietary intake
  • Increased requirement (e.g., infancy, hemolytic anemia)
  • Malabsorption syndromes

2. Non-Megaloblastic Causes

• Liver disease
• Hypothyroidism
• Reticulocytosis (e.g., hemolysis, blood loss)
• Bone marrow disorders (e.g., aplastic anemia, myelodysplasia)
• Drug-induced (e.g., anticonvulsants, chemotherapy)

---

Pathophysiology

In megaloblastic anemia, impaired DNA synthesis leads to delayed nuclear maturation while cytoplasmic development proceeds normally. This nuclear-cytoplasmic asynchrony results in large, immature erythroid precursors (megaloblasts) and macrocytic RBCs in circulation.

Vitamin B12 and folate are essential cofactors in DNA synthesis. Deficiency of either disrupts thymidine production, impairing cell division.

---

Clinical Features

Clinical presentation varies depending on severity and cause:

• General symptoms
  • Pallor
  • Fatigue
  • weakness
• Gastrointestinal
  • Glossitis (smooth, red tongue)
  • Poor appetite
• Neurological (especially in B12 deficiency)
  • Paresthesia
  • Ataxia
  • Developmental delay (in infants)

---

Laboratory Findings

• Elevated MCV (>100 fL)
• Hypersegmented neutrophils (hallmark of megaloblastic anemia)
• Low hemoglobin
• Peripheral smear: macro-ovalocytes
• Serum levels:
  • ↓ Vitamin B12
  • ↓ Folate
• Elevated homocysteine (both deficiencies)
• Elevated methylmalonic acid (specific for B12 deficiency)

---

Diagnosis

Diagnosis involves:

1. Complete blood count (CBC)
2. Peripheral blood smear
3. Serum vitamin B12 and folate levels
4. Bone marrow examination (if unclear or severe cases)

---

Management

Vitamin B12 Deficiency

• Parenteral B12 (cyanocobalamin or hydroxocobalamin)
• Lifelong therapy in irreversible causes

Folate Deficiency

• Oral folic acid supplementation
• Treat underlying cause

⚠️ Important: Always rule out B12 deficiency before treating folate deficiency alone, as folate can worsen neurological symptoms of B12 deficiency.

---

Complications

• Neurological deficits (irreversible if untreated)
• Growth retardation in children
• Increased risk of infections due to pancytopenia

---

Prevention

• Adequate dietary intake (green leafy vegetables, animal products)
• Supplementation in high-risk groups
• Early detection in infants and children

---

Conclusion

Macrocytic anemia in children requires a systematic approach to identify underlying causes. As emphasized in Nelson Textbook of Pediatrics, distinguishing between megaloblastic and non-megaloblastic anemia is critical for appropriate management. Early diagnosis and treatment can prevent serious complications, particularly irreversible neurological damage in vitamin B12 deficiency.

---

Diamond-Blackfan anemia (DBA) is a rare congenital blood disorder characterized by the failure of the bone marrow to produce red blood cells. It usually presents in infancy and is classified as a congenital pure red cell aplasia. DBA is notable for its genetic basis, variable physical malformations, and lifelong management challenges.

Key facts

• Onset: Typically within the first year of life
• Genetic cause: Mutations in ribosomal protein genes
• Inheritance pattern: Autosomal dominant (most cases de novo)
• Prevalence: About 5–7 per million live births
• Treatment options: Corticosteroids, chronic transfusions, or stem cell transplantation

Pathophysiology

Diamond-Blackfan anemia arises from mutations that impair ribosome biogenesis, leading to defective erythroid progenitor development. The bone marrow becomes selectively deficient in red cell precursors, while white cells and platelets remain normal. Most cases involve mutations in genes encoding ribosomal proteins such as RPS19, RPL5, or RPL11, disrupting protein synthesis and cellular growth.

Clinical features

Infants with DBA commonly present with pallor and anemia. Physical anomalies are present in about half of cases, including craniofacial abnormalities, thumb or limb malformations, and heart or kidney defects. Growth retardation and an increased lifetime risk of malignancies such as leukemia and osteogenic sarcoma are recognized complications.

Diagnosis

Diagnosis combines hematologic findings—macrocytic anemia, reticulocytopenia, and normal marrow cellularity except for absent red cell precursors—with genetic testing for ribosomal protein gene mutations. Elevated erythrocyte adenosine deaminase (eADA) activity is a common biomarker.

Management and prognosis

Initial treatment often involves corticosteroids to stimulate red cell production. Patients unresponsive to steroids may require regular transfusions with iron chelation therapy to prevent overload, or hematopoietic stem cell transplantation as a potential cure. Advances in genetic understanding have improved prognosis, but lifelong monitoring remains essential due to treatment complications and cancer risk.